Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):344-345. Epub 2019 Mar 7.

Authors

Eric Toussirot¹, Claude Bernard², Marie Bossert³

Affiliations

¹ INSERM CIC-1431, Clinical Investigation Center in Biotherapy; Fédération Hospital-Universitaire INCREASE; Dept. of Rheumatology, University Hospital of Besançon; Univ. of Bourgogne Franche-Comté, Dept. of Therapeutics and EPILAB EA4266, Besançon, France.
² Department of Nephrology, Hôpital Nord Franche-Comté, Trevenans, France.
³ Department of Rheumatology, Hôpital Nord Franche-Comté, Trevenans, France.

PMID: 30873944

No abstract available

Publication types

Letter

MeSH terms

Certolizumab Pegol / adverse effects
Humans
Immunoglobulin Fab Fragments
Interleukin-17 / antagonists & inhibitors*
Sarcoidosis* / chemically induced
Sarcoidosis* / drug therapy

Substances

IL17A protein, human
Immunoglobulin Fab Fragments
Interleukin-17
Certolizumab Pegol